Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept.

about

Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept.

Item

http://www.wikidata.org/entity/Q47121012

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Proteoglycan-targeting applied ...... rcoma: first proof-of-concept.

@en

Proteoglycan-targeting applied ...... rcoma: first proof-of-concept.

@nl

type

Item

label

Proteoglycan-targeting applied ...... rcoma: first proof-of-concept.

@en

Proteoglycan-targeting applied ...... rcoma: first proof-of-concept.

@nl

prefLabel

Proteoglycan-targeting applied ...... rcoma: first proof-of-concept.

@en

Proteoglycan-targeting applied ...... rcoma: first proof-of-concept.

@nl

P1476

Proteoglycan-targeting applied ...... arcoma: first proof-of-concept

@en

P2093

Aurélien Voissiere

http://www.w3.org/2001/XMLSchema#string

Caroline Peyrode

http://www.w3.org/2001/XMLSchema#string

Elisabeth Miot-Noirault

http://www.w3.org/2001/XMLSchema#string

Florian Raes

http://www.w3.org/2001/XMLSchema#string

Françoise Rédini

http://www.w3.org/2001/XMLSchema#string

Valérie Weber

http://www.w3.org/2001/XMLSchema#string

Yvain Gerard

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Targeting hypoxic response for cancer therapy

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs

Generation of Multicellular Tumor Spheroids with Microwell-Based Agarose Scaffolds for Drug Testing

Influence of tumour micro-environment heterogeneity on therapeutic response

A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

A"Proteoglycan targeting strategy" for the scintigraphic imaging and monitoring of the swarm rat chondrosarcoma orthotopic model

The clinical approach towards chondrosarcoma.

New horizons in tumor microenvironment biology: challenges and opportunities

Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.

P304

95824-95840

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.21337

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Michel Chezal

F Degoul

P577

2017-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29221170

http://www.w3.org/2001/XMLSchema#string

P921

chondrosarcoma

P932

5707064

http://www.w3.org/2001/XMLSchema#string